26 Sep 2021
Why durability matters: lifetime management considerations for supra-annular TAVR
Sponsored by Medtronic
Anchorperson:
S. Saito
Moderator:
D. Roy
Summary
In this session, the speakers address the problem of the evolution of clinical data for TAVI from extreme to low risk based on a number of studies on the subject, such as CoreValve Pivotal Study, Partner Study, SURTAVI Study, or Evolut Low-Risk Study, and then focus on the issues of patient-prosthesis mismatch, structural valve deterioration, and bioprosthetic aortic valve degeneration by referring to the 2020 ACC/AHA Guidelines for the management of patients with valvular heart disease.
Learning Objectives
- To review the clinical data evolution from extreme high to low risk
- To learn about the latest Evolut low-risk result
- To discuss the lifetime management consideration for low-risk patients especially Asian patients
